Author:
Dummer Reinhard,Lear John T.,Guminski Alex,Leow Liang Joo,Squittieri Nicholas,Migden Michael
Reference5 articles.
1. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management;Marzuka;Yale J Biol Med,2015
2. Odomzo (sonidegib capsules). Full prescribing information. Sun Pharmaceutical Industries, Inc., Cranbury, NJ.
3. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial;Migden;Lancet Oncol,2015
4. Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial
5. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study;Lear;J Eur Acad Dermatol Venereol,2018
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献